by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia
Abstract INTRODUCTION Plasma phosphorylated tau (p-tau)217 is increasingly used to triage amyloid testing, but the biological and clinical meaning of discordant plasma p-tau217 and amyloid positron emission tomography (PET) results in cognitively normal adults remains...
by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia
Abstract INTRODUCTION Epigenetic dysregulation is increasingly linked to aging and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer’s disease (AD) remains unclear. METHODS We quantified the repressive epigenetic mark histone H3...
by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia
ABSTRACT INTRODUCTION Diabetes is a major risk factor for Alzheimer’s disease (AD), and both diseases involve mitochondrial dysfunction. Changes in mitochondrial DNA (mtDNA) can influence energy metabolism, cellular signaling, and epigenetic programming, thereby...
by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Neuroscience
Nature Neuroscience, Published online: 20 October 2026; doi:10.1038/s41593-026-02487-7This study identifies ABCA1 as a driver of dysregulated cholesterol trafficking in Parkinson’s disease, showing that reducing ABCA1 in astrocytes and neurons decreases cholesterol...
by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Neuroscience
Nature Neuroscience, Published online: 20 October 2026; doi:10.1038/s41593-026-02485-9Sensory and motor-associative identities in the thalamus arise from two early-diverging lineages, with sensory neurons progressing through shared intermediate states, revealing how...
